Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Tenon Medical Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Neuropace Inc. June 6, 202574.1%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 19, 2026 | Neuropace Inc. | Grant or award | +1,467 | $15.63 | $22,929 |
| Jun 5, 2026 | Neuropace Inc. | Grant or award | +2,890 | — | — |
| Mar 20, 2026 | Neuropace Inc. | Grant or award | +1,826 | $13.00 | $23,738 |
| Dec 19, 2025 | Neuropace Inc. | Grant or award | +1,431 | $16.59 | $23,740 |
| Sep 19, 2025 | Neuropace Inc. | Grant or award | +2,389 | $9.94 | $23,747 |
| Jun 21, 2025 | Neuropace Inc. | Grant or award | +2,281 | $10.41 | $23,745 |
| Mar 21, 2025 | Neuropace Inc. | Grant or award | +1,975 | $12.02 | $23,740 |
| Dec 21, 2024 | Neuropace Inc. | Grant or award | +2,059 | $11.53 | $23,740 |
| Sep 30, 2024 | Neuropace Inc. | Grant or award | +3,407 | $6.97 | $23,747 |
| Jun 28, 2024 | Neuropace Inc. | Grant or award | +3,141 | $7.56 | $23,746 |
| Mar 29, 2024 | Neuropace Inc. | Grant or award | +1,799 | $13.20 | $23,747 |
| Dec 29, 2023 | Neuropace Inc. | Grant or award | +2,303 | $10.31 | $23,744 |
| Sep 29, 2023 | Neuropace Inc. | Grant or award | +2,440 | $9.73 | $23,741 |
| Jun 30, 2023 | Neuropace Inc. | Grant or award | +4,469 | $4.49 | $20,066 |
| May 22, 2023 | Tenon Medical Inc. | Option exercise | +6,207 | $1.62 | $10,055 |
Questions about Frank M. Fischer
What boards is Frank M. Fischer on?
Frank M. Fischer sits on the boards of Neuropace Inc. and Tenon Medical Inc.
How long has Frank M. Fischer served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.